Bellevue Life Sciences Acquisition in an 8-K said shareholders approved a deadline extension to April 2024, while redemptions claimed about 38% of the outstanding stock.
The extension requires a $180,000 deposit into trust for the first extension period through Feb. 14. Beyond then, the SPAC would have to deposit the lesser of $60,000 or 2.6 cents a share for each of the remaining two months.
Bellevue Life Sciences in July signed an exclusive, non-binding letter of intent with OSR, a healthcare holding company. The LOI is not mentioned in the SPAC’s latest regulatory filing. Read more.
